Less than 1 min.Read

Imugene: Receives key U.S. patent for cancer therapies

October 2, 2020

Imugene (IMU) shares are trading green today on news the healthcare stock was granted a core U.S. patent
The patent protects Imugene’s B-Cell immunotherapy portfolio, which includes a range of cancer vaccines
Specifically, the new patient protects the composition and use of the vaccines, which are licenced by Ohio State University
Imugene’s CEO and Managing Director, Leslie Chong, said winning the key U.S. patent is a significant step for the company
The patent is valid up until 2035
Today, Imugene shares are up 3.92 per cent to trade for 5.3 cents each